Foto / Video
Contattaci
Lavorare in NMS
Cerca
Home
NMS Company
Chi Siamo
Organi Statutari
Mission
News
Archivio
Storia e Track record
Licensing e Collaborazioni
Information Technology
Lavorare in NMS
Come Raggiungere NMS
Informazioni Legali
Oncology
About NMS Oncology
Intellectual Property
Pipeline
Nemorubicin
Danusertib
Milciclib
NMS-1116354
NMS-1286937
Preclinical Programs
Technology Platforms
Payloads and Antibody Drug Conjugates (ADCs)
Capabilities
Lead Optimization and Medicinal Chemistry
Fragment Based Drug Discovery
NMR Screening
Cell Assay Technologies
Cell Bank and Cell Proliferation
Collaborations
Science Corner
Eventi e Congressi
Pubblicazioni
Seminari di Oncologia
M.I.O.
Milano International Oncology
Expertise
Partnerships
Capabilities
Core services
Accelera
NerPharMa / DS
Archive
1
A new agreement has stated the official separation between Nerviano Medical Sciences and Pfizer.
Giu 2, 2010
2
In JCO, Danusertib results of a Phase 1 trial. Phase 2 in patients with lung cancer and other solid tumors ongoing.
Ott 8, 2009
3
FDA approves clinical studies of a novel anti-cancer drug developed by the Italian research
Feb 10, 2009
4
Nerviano Medical Sciences announces a new Collaboration Agreement with Genentech to discover Antibody Drug Conjugates
Ott 21, 2008
5
The DNDi Project of the Year: The Development of Fexinidazole to Treat "Sleeping Sickness".
Giu 27, 2008
6
Three Nerviano Medical Sciences molecules at ASCO
Giu 2, 2008
7
NMS DEVELOPS A NOVEL APPROACH FOR CANCER TREATMENT
Mag 20, 2008
8
Pagina in manutenzione
Mag 19, 2008
9
Students face to face with science
Mag 13, 2008
10
Important new discoveries from NMS on Cdc7 inhibitor, a protein responsible for the proliferation of tumour cells
Apr 15, 2008
Inizio
Prec
1
2
Succ
Fine
Pagina 1 di 2
NMS Company
Chi Siamo
Organi Statutari
Mission
News
Archivio
Storia e Track record
Licensing e Collaborazioni
Information Technology
Lavorare in NMS
Come Raggiungere NMS
Informazioni Legali